US · CTSO · MEDICAL - DEVICES
Cytosorbents Corporation (CTSO) intrinsic value and stock valuation
$4.16as of 2026-11-21 · Mkt cap 22.62M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Cytosorbents Corporation DCF and intrinsic value
InvestorsCraft values CTSO with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from CTSO’s statements →
Cytosorbents Corporation Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Biodesix, Inc. (BDSX) $7.56
- electroCore, Inc. (ECOR) $4.42
- Spectral AI, Inc. (MDAI) $1.04
- Sensus Healthcare, Inc. (SRTS) $2.26
- Baird Medical Investment Holdings Limited (BDMD) $0.09
- TELA Bio, Inc. (TELA) $0.69
- Telomir Pharmaceuticals, Inc. Common Stock (TELO) $0.36
- NeuroOne Medical Technologies Corporation (NMTC) $0.65
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $37.1M | $35.6M | $31.1M | $34.7M | $40.1M |
| Operating income | -$-14.24M | -$-16.45M | -$-31.95M | -$-31.52M | -$-22.74M |
| Net income | -$-8.2M | -$-20.72M | -$-29.25M | -$-32.81M | -$-24.56M |
| EPSd | -$-131.77K | -$-380.67K | -$-654.95K | -$-753.04K | -$-566.42K |
| Operating cash flow | -$-12.38M | -$-14.43M | -$-21.66M | -$-28.23M | -$-14.01M |
| Capital expenditure | -$-160K | -$-280K | -$-940K | -$-6.46M | -$-4.28M |
| Free cash flow | -$-12.54M | -$-14.71M | -$-22.59M | -$-34.69M | -$-18.29M |
| Total assets | $44.2M | $47.4M | $53.3M | $63.2M | $89.5M |
| Total debt | $29.1M | $26.9M | $18.3M | $18.3M | $13.8M |
| Net debt | $22.9M | $23.6M | $4.18M | -$-3.89M | -$-38.32M |
| Total equity | $5.9M | $11.1M | $23.3M | $35.4M | $62.6M |
| Cash and short-term investments | $6.25M | $3.28M | $14.1M | $22.1M | $52.1M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $37.1M | $35.6M | $31.1M | $34.7M | $40.1M |
| Cost of revenue | $10.6M | $10.7M | $9.13M | $14M | $11.1M |
| Gross profit | $26.5M | $24.9M | $22M | $20.7M | $29.1M |
| Research and development expenses | $5.08M | $7.61M | $15.6M | $15.1M | $16.4M |
| Selling, general and administrative expenses | $35.7M | $33.7M | $38.3M | $2.79M | $38.5M |
| Other expenses | $0.00 | $0.00 | $0.00 | $34.3M | -$-3.06M |
| Operating expenses | $40.7M | $41.3M | $53.9M | $52.3M | $51.8M |
| Cost and expenses | $51.3M | $52.1M | $63M | $66.2M | $62.9M |
| Interest income | $0.00 | $0.00 | $0.00 | $130K | $30K |
| Interest expense | $2.61M | $1.4M | $160K | $0.00 | $0.00 |
| Depreciation and amortization | $1.63M | $1.74M | $2.02M | $880K | $1.13M |
| Ebitda | -$-4.36M | -$-19.27M | -$-27.88M | -$-30M | -$-24.17M |
| Operating income | -$-14.24M | -$-16.45M | -$-31.95M | -$-31.52M | -$-22.74M |
| Total other income/expenses, net | $5.64M | -$-5.96M | $1.89M | -$-2.38M | -$-2.55M |
| Income before tax | -$-8.6M | -$-22.41M | -$-30.06M | -$-33.91M | -$-25.29M |
| Income tax expense | -$-400K | -$-1.69M | -$-810K | -$-1.09M | -$-740K |
| Net income | -$-8.2M | -$-20.72M | -$-29.25M | -$-32.81M | -$-24.56M |
| Weighted average shares outstanding | $62.2M | $54.4M | $44.7M | $43.6M | $43.4M |
| Weighted average diluted shares outstanding | $62.2M | $54.4M | $44.7M | $43.6M | $43.4M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $6.25M | $3.28M | $14.1M | $22.1M | $52.1M |
| Net receivables | $7.55M | $7.32M | $6.06M | $5.66M | $4.52M |
| Inventory | $5.28M | $2.73M | $3.68M | $3.46M | $4.77M |
| Total current assets | $20.6M | $21.6M | $25.7M | $33.8M | $64.3M |
| Property, plant and equipment, net | $18.8M | $20.5M | $22.1M | $23.4M | $18.6M |
| Goodwill and intangible assets | $3.23M | $3.75M | $3.91M | $4.39M | $4.7M |
| Long-term investments | $1.52M | $0.00 | $1.48M | $1.73M | $1.94M |
| Total non-current assets | $23.6M | $25.8M | $27.6M | $29.5M | $25.2M |
| Total assets | $44.2M | $47.4M | $53.3M | $63.2M | $89.5M |
| Accounts payable | $2.87M | $3.34M | $3.8M | $1.66M | $2.81M |
| Short-term debt | $540K | $450K | $2.87M | $110K | $570K |
| Deferred revenue | $330K | $420K | $1.38M | $1.52M | $1.95M |
| Total current liabilities | $9.71M | $9.82M | $14.6M | $9.71M | $13.7M |
| Long-term debt | $28.6M | $26.4M | $15.4M | $18.1M | $13.3M |
| Deferred revenue, non-current | $0.00 | $0.00 | -$-3.71M | $0.00 | $0.00 |
| Total non-current liabilities | $28.6M | $26.4M | $15.4M | $18.1M | $13.3M |
| Capital lease obligations | $12.4M | $12.9M | $13.3M | $13.1M | $13.3M |
| Total liabilities | $38.3M | $36.3M | $30M | $27.9M | $26.9M |
| Common stock | $60K | $50K | $50K | $40K | $40K |
| Retained earnings | -$-312.21M | -$-304.01M | -$-282.51M | -$-254M | -$-221.19M |
| Accumulated other comprehensive income (loss) | -$-2.98M | $4.25M | $530K | $2.33M | $530K |
| Total equity | $5.9M | $11.1M | $23.3M | $35.4M | $62.6M |
| Total investments | $1.52M | $0.00 | $1.48M | $1.73M | $1.94M |
| Total debt | $29.1M | $26.9M | $18.3M | $18.3M | $13.8M |
| Net debt | $22.9M | $23.6M | $4.18M | -$-3.89M | -$-38.32M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-8.2M | -$-20.72M | -$-28.51M | -$-32.81M | -$-24.56M |
| Depreciation and amortization | $950K | $1.75M | $2.03M | $1.13M | $1.13M |
| Stock-based compensation | $2.77M | $3.76M | $3.7M | $3.8M | $6.2M |
| Change in working capital | -$-1.03M | -$-4.38M | $2.36M | -$-3.56M | $640K |
| Accounts receivable | $420K | -$-1.72M | -$-250K | -$-1.29M | $420K |
| Inventory | -$-2.54M | $500K | -$-120K | $950K | -$-2.35M |
| Accounts payable | -$-710K | -$-1.81M | $1.62M | -$-3.25M | $2.43M |
| Net cash provided by operating activities | -$-12.38M | -$-14.43M | -$-21.66M | -$-28.23M | -$-14.01M |
| Investments in property, plant and equipment | -$-160K | -$-670K | -$-940K | -$-6.46M | -$-4.28M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | -$-410K | -$-670K | -$-940K | -$-6.46M | -$-4.28M |
| Common stock issued | $6.83M | $180K | $14.3M | -$-40K | $720K |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $9.31M | $9.33M | $14.5M | $4.96M | $720K |
| Net change in cash | -$-1.99M | -$-5.85M | -$-8.22M | -$-29.99M | -$-17.6M |
| Cash at end of period | $7.77M | $9.76M | $15.6M | $23.8M | $53.8M |
| Operating cash flow | -$-12.38M | -$-14.43M | -$-21.66M | -$-28.23M | -$-14.01M |
| Capital expenditure | -$-160K | -$-280K | -$-940K | -$-6.46M | -$-4.28M |
| Free cash flow | -$-12.54M | -$-14.71M | -$-22.59M | -$-34.69M | -$-18.29M |
Line items
Line items
Line items
About Cytosorbents Corporation
Cytosorbents Corporation specializes in creating and bringing to market innovative medical devices. Their core expertise lies in a unique blood purification platform, built upon a proprietary adsorbent and porous polymer technology. The company's leading product, CytoSorb, is an extracorporeal filter designed to remove cytokines from the blood. It serves as a complementary treatment in various critical care scenarios, including sepsis, managing complications during and after heart bypass surgery, and improving the viability of donor organs for transplantation. Beyond CytoSorb, Cytosorbents offers a portfolio of specialized devices. These include VetResQ, used to assist in treating critical conditions like sepsis and pancreatitis in animals; CytoSorb-XL, another device targeting sepsis and other severe illnesses; HemoDefend, a platform for purifying blood supplies by removing contaminants that cause transfusion reactions and diseases, as well as anti-A and anti-B antibodies from blood products; K+ontrol, designed for patients with severe, life-threatening hyperkalemia; and ContrastSorb, which extracts intravenous contrast agents following imaging procedures (like CT scans, angiograms, or interventional radiology) to mitigate the risk of contrast-induced kidney damage. The company is also actively developing several new solutions: BetaSorb, aimed at preventing and treating complications from metabolic toxin buildup in chronic kidney disease patients; DrugSorb, which focuses on eliminating harmful chemicals from the bloodstream; and DrugSorb-ATR, an innovative system for removing antithrombotic agents. Originally established as MedaSorb Technologies Corporation in 1997, the company adopted its current name, Cytosorbents Corporation, in May 2010. Its corporate headquarters are situated in Princeton, New Jersey.
- CEO
- Phillip Chan
- Employees
- 129
- Beta
- 1.39
Explore
Frequently asked questions
What is the intrinsic value of Cytosorbents Corporation (CTSO)?
Cytosorbents Corporation (CTSO) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is CTSO undervalued?
CTSO trades at a price of $4.16 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.